Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02780804 : Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
PhasePhase 1
AgesMin: 12 Months Max: 21 Years
Eligibility
Inclusion Criteria:

- Patients must have a body surface area (BSA) of >= 1.17 m^2 at time of study
enrollment

- Patients must be able to swallow intact tablets

- Patients with recurrent or refractory solid tumors, including central nervous system
(CNS) tumors or lymphoma, are eligible; patients must have had histologic verification
of malignancy at original diagnosis or relapse except in patients with intrinsic brain
stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of
cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or
beta-human chorionic gonadotropin (HCG)

- Patients must have either measurable or evaluable disease

- Patient's current disease state must be one for which there is no known curative
therapy or therapy proven to prolong survival with an acceptable quality of life

- Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16
years of age; Note: neurologic deficits in patients with CNS tumors must have been
relatively stable for at least 7 days prior to study enrollment; patients who are
unable to walk because of paralysis, but who are up in a wheelchair, will be
considered ambulatory for the purpose of assessing the performance score

- Patients must have fully recovered from the acute toxic effects of all prior
anti-cancer therapy and must meet the following minimum duration from prior
anti-cancer directed therapy prior to enrollment; if after the required timeframe, the
defined eligibility criteria are met, e.g. blood count criteria, the patient is
considered to have recovered adequately

- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive;
the duration of this interval must be discussed with the study chair and the
study-assigned research coordinator prior to enrollment

- Solid tumor patients: >= 21 days after the last dose of cytotoxic or
myelosuppressive chemotherapy (42 days if prior nitrosourea)

- Lymphoma patients: a waiting period prior to enrollment is not required for
patients receiving standard cytotoxic maintenance chemotherapy (i.e.
corticosteroid, vincristine, thioguanine[6MP], and/or methotrexate)

- >=14 days must have elapsed after the completion of other cytotoxic therapy,
with the exception of hydroxyurea, for patients not receiving standard
maintenance therapy; additionally, patients must have fully recovered from
all acute toxic effects of prior therapy; Note: cytoreduction with
hydroxyurea must be discontinued >= 24 hours prior to the start of protocol
therapy

- Anti-cancer agents not known to be myelosuppressive (e.g. not associated with
reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days must have
elapsed from the last dose of agent; the duration of this interval must be
discussed with the study chair and the study-assigned research coordinator prior
to enrollment

- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody,
and toxicity related to prior antibody therapy must be recovered to grade =< 1

- Hematopoietic growth factors: >= 14 days must have elapsed from the last dose of
a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting
growth factor; for agents that have known adverse events occurring beyond 7 days
after administration, this period must be extended beyond the time during which
adverse events are known to occur; the duration of this interval must be
discussed with the study chair and the study-assigned research coordinator

- Interleukins, interferons and cytokines (other than hematopoietic growth
factors): >= 21 days must have elapsed from the last dose of interleukins,
interferon or cytokines (other than hematopoietic growth factors)

- Stem cell infusions (with or without traumatic brain injury [TBI]):

- Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem
cell infusion including donor lymphocyte infusion (DLI) or boost infusion:
>= 84 days must have elapsed from infusion and no evidence of graft versus
host disease (GVHD)

- Autologous stem cell infusion including boost infusion: >= 42 days must have
elapsed from infusion

- Cellular therapy: >= 42 days must have elapsed from last dose of any type of
cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic
cells, etc.)

- External beam radiation (XRT)/External beam irradiation including protons: >= 14
days must have elapsed after local XRT; >= 150 days after TBI, craniospinal XRT
or if radiation to 50% of the pelvis; >= 42 days if other substantial bone marrow
(BM) radiation

- Radiopharmaceutical therapy (e.g., radiolabeled antibody, iobenguane I-131
[131I-MIBG]): >= 42 days must have elapsed from the last dose of systemically
administered radiopharmaceutical therapy

- Histone deacetylase (HDAC) inhibitors: Patients must not have received prior
therapy with entinostat; patients who have received therapy with other HDAC
inhibitors are eligible

- Peripheral absolute neutrophil count ( ANC) >= 1000/mm^3

- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving
platelet transfusions for at least 7 days prior to enrollment)

- Hemoglobin >= 8.0 g/dl, with or without transfusion

- Patients with known bone marrow metastatic disease will not be eligible

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

- 1 to < 2 years: 0.6 mg/dL for males and females

- 2 to < 6 years: 0.8 mg/dL for males and females

- 6 to < 10 years: 1.0 mg/dL for males and females

- 10 to < 13 years: 1.2 mg/dL for males and females

- 13 to < 16 years: 1.5 mg/dL for males and 1.4 mg/dL for females

- > = 16 years: 1.7 mg/dL for males and 1.4 mg/dL for females

- Bilirubin =< 1.5 x upper limit of normal (ULN) for age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110
U/l; for the purpose of this study, the ULN for SGPT is 45 U/l

- Serum albumin >= 2 g/dl

- All patients and/or their parents or legally authorized representatives must sign a
written informed consent; assent, when appropriate, will be obtained according to
institutional guidelines

Exclusion Criteria:

- Pregnant or breast-feeding women will not be entered on this study; pregnancy tests
must be obtained in girls who are post-menarchal; males or females of reproductive
potential may not participate unless they have agreed to use an effective
contraceptive method both during and for 3 months after participation in this study;
abstinence is an acceptable method of contraception; those who become pregnant while
on treatment with entinostat must discontinue immediately and consult their treating
physician

- Patients receiving corticosteroids who have not been on a stable or decreasing dose of
corticosteroid for at least 7 days prior to enrollment are not eligible; if used to
modify immune adverse events related to prior therapy, >= 14 days must have elapsed
since last dose of corticosteroid

- Patients who are currently receiving another investigational drug are not eligible

- Patients who are currently receiving other anti-cancer agents are not eligible

- Patients requiring concurrent administration of valproic acid are not eligible for
this trial

- Patients who are receiving cyclosporine, tacrolimus or other agents to prevent
graft-versus-host disease post bone marrow transplant are not eligible for this trial

- Patients with a BSA ? 1.17 m^2 at time of study enrollment are not eligible

- Patients who are not able to swallow intact tablets are not eligible

- Patients who have an uncontrolled infection are not eligible

- Patients who have received a prior solid organ transplantation are not eligible

- Patients who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study are not eligible

- Patients with a history of allergy to medications that have a benzamide structure
(e.g., metoclopramide, procarbazine, domperidone, cisapride etc.) are not eligible
LinksPermanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT02780804      |      Link to official Clinicaltrials.gov listing
Locations
Birmingham, Alabama
Facility: Children's Hospital of Alabama
Investigator: Alyssa T. Reddy
Contact: Alyssa T. Reddy Phone: 888-823-5923
Click HERE to send email to this center

Los Angeles, California
Facility: Children's Hospital Los Angeles
Investigator: Leo Mascarenhas
Contact: Leo Mascarenhas Phone: 888-823-5923
Click HERE to send email to this center

Orange, California
Facility: Children's Hospital of Orange County
Investigator: Ivan I. Kirov
Contact: Ivan I. Kirov Phone: 888-823-5923
Click HERE to send email to this center

San Francisco, California
Facility: UCSF Medical Center-Mission Bay
Investigator: Kieuhoa T. Vo
Contact: Kieuhoa T. Vo Phone: 877-827-3222
Email not avaialable

Washington, D.C., District of Columbia
Facility: Children's National Medical Center
Investigator: AeRang Kim
Contact: AeRang Kim Phone: 800-411-1222
Email not avaialable

Atlanta, Georgia
Facility: Children's Healthcare of Atlanta - Egleston
Investigator: William T. Cash
Contact: William T. Cash Phone: 888-823-5923
Click HERE to send email to this center

Chicago, Illinois
Facility: Lurie Children's Hospital-Chicago
Investigator: Stewart Goldman
Contact: Stewart Goldman Phone: 888-823-5923
Click HERE to send email to this center

Indianapolis, Indiana
Facility: Riley Hospital for Children
Investigator: James M. Croop
Contact: James M. Croop Phone: 800-248-1199
Email not avaialable

Boston, Massachusetts
Facility: Dana-Farber Cancer Institute
Investigator: Steven G. DuBois
Contact: Steven G. DuBois Phone: 877-827-3222
Email not avaialable

Ann Arbor, Michigan
Facility: C S Mott Children's Hospital
Investigator: Rajen Mody
Contact: Rajen Mody Phone: 888-823-5923
Click HERE to send email to this center

Minneapolis, Minnesota
Facility: University of Minnesota/Masonic Cancer Center
Investigator: Emily G. Greengard
Contact: Emily G. Greengard Phone: 888-823-5923
Click HERE to send email to this center

Saint Louis, Missouri
Facility: Washington University School of Medicine
Investigator: Robert J. Hayashi
Contact: Robert J. Hayashi Phone: 800-600-3606
Click HERE to send email to this center

New York, New York
Facility: Columbia University/Herbert Irving Cancer Center
Investigator: Julia Glade-Bender
Contact: Julia Glade-Bender Phone: 212-305-8615
Email not avaialable

Cincinnati, Ohio
Facility: Cincinnati Children's Hospital Medical Center
Investigator: David A. Geller
Contact: David A. Geller Phone: 412-647-8073
Email not avaialable

Portland, Oregon
Facility: Oregon Health and Science University
Investigator: Suman Malempati
Contact: Suman Malempati Phone: 503-494-1080
Click HERE to send email to this center

Philadelphia, Pennsylvania
Facility: Children's Hospital of Philadelphia
Investigator: Elizabeth Fox
Contact: Elizabeth Fox Phone: 800-411-1222
Email not avaialable

Pittsburgh, Pennsylvania
Facility: Children's Hospital of Pittsburgh of UPMC
Investigator: Jean M. Tersak
Contact: Jean M. Tersak Phone: 888-823-5923
Click HERE to send email to this center

Memphis, Tennessee
Facility: St. Jude Children's Research Hospital
Investigator: Wayne L. Furman
Contact: Wayne L. Furman Phone: 888-823-5923
Click HERE to send email to this center

Houston, Texas
Facility: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Investigator: Jodi Muscal
Contact: Jodi Muscal Phone: 713-798-1354
Click HERE to send email to this center

Seattle, Washington
Facility: Seattle Children's Hospital
Investigator: Julie R. Park
Contact: Julie R. Park Phone: 888-823-5923
Click HERE to send email to this center




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites